Feeds › Clinical trial updates
Clinical trial updates
Drug and device trials that companies register on ClinicalTrials.gov: newly completed phase 3 studies, changes of status and the dates a study is due to finish.
About this data
- What it is
- ClinicalTrials.gov is the US registry of clinical studies. Drug and device makers register their trials there and update the record as each study moves on. We list the studies that companies sponsor, and match the sponsor to a public company when the name lines up. The page opens on Phase 3 studies marked completed, the late-stage trials that come before a request for approval. Change View to see the changes of status we have noticed, or every recent update.
- Who files it
- The sponsor of the study, in its record on ClinicalTrials.gov. The registry is run by the US National Library of Medicine and does not check what sponsors report.
- How current
- We check the registry every day. Sponsors update records on their own schedule, from the same week to months later, so a change can appear in the registry well after it happened.
- Terms
- ClinicalTrials.govClinicalTrials.gov is the US government's registry of clinical studies, run by the National Library of Medicine. Sponsors register a study before it starts and update the record as it goes. The registry does not check what a sponsor reports.Phase 3The late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages.statusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time).completedThe sponsor has marked the study as finished. It says nothing about whether the treatment worked: results, if any, are reported separately and often later.status changesOur history of status changes starts the day we first stored each study, so a change made before that is not shown. The date is when we noticed the change, which can be later than when the sponsor made it.primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update.company matchWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private.
- Worth knowing
- A completed study is not a result: the registry says the study ended, not whether the treatment worked. Status changes start on the day we first stored each study, so earlier changes are not shown. Dates are the sponsor's own, and an estimated date can pass without an update. We match sponsors to companies automatically, with a hand-checked list for the large drugmakers, so a study with no ticker may still belong to a public company. This is information about studies, not a forecast of what they will show or of a stock's price.
- Not to be confused with
- FDA approvals and clearances: what the FDA decided, not what a sponsor reports about a study.
All of this comes from ClinicalTrials.gov, the US registry of clinical studies. We are not affiliated with it.
Source and freshness · Information, not investment advice (disclaimer).
Studies updated per day, last 30 days
All industry-sponsored studies Sponsor matched to a public company
By the day the sponsor last updated the study's record. A study updated twice counts once, on its latest day.
Latest clinical trial updates
Showing: ticker BMY · All recent updates
Studies by the date their record was last updated.
| Updated | Study | SponsorWe match the sponsor's name to a public company automatically, and by hand for the large drugmakers. A subsidiary or a differently spelled name can be missed, so a study with no ticker does not mean the sponsor is private. | PhaseThe late stage of testing, usually with hundreds or thousands of people, to confirm that a treatment works and to find side effects. A study marked Phase 2/3 covers both stages. | StatusThe registry's own word for where a study stands: not yet recruiting, recruiting, active but not recruiting, completed, terminated (stopped early), withdrawn (never started), suspended, or unknown (the sponsor has not confirmed the record for a long time). | Enrolled | Primary completionThe date the last participant is examined for the main question the study asks. The study can run on after it, for follow-up. Sponsors enter the date and revise it, and an estimated date can pass without an update. | Source |
|---|---|---|---|---|---|---|---|
| Nov 13, 2026 | A Study to Compare the Combination of Navlimetostat (BMS-986504) With Pembrolizumab and Chemotherap… NCT07063745 · Metastatic Non-small Cell Lung Cancer With MTAP Deletion BMS-986504, Pembrolizumab | BMY Bristol-Myers Squibb | Phase 2/3 | Recruiting | 590 | Aug 12, 2031 | Registry ↗ |
| Nov 12, 2026 | A Solid Tumor Study for Long Term Treatment of Cancer Patients Who Participated in Adagrasib Studies NCT07415031 · Solid Tumors Adagrasib, Pembrolizumab | BMY Mirati Therapeutics Inc. | Phase 2 | Recruiting | 170 | Feb 16, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Schizophrenia in Adolesce… NCT07288567 · Schizophrenia KarXT, KarXT Matching Placebo | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 166 | Dec 18, 2029 | Registry ↗ |
| Nov 12, 2026 | Study of Izalontamab Brengitecan (BMS-986507) Versus Platinum-based Chemotherapy With or Without Am… NCT07100080 · Non-Small Cell Lung Cancer Iza-bren, Carboplatin | BMY Bristol-Myers Squibb | Phase 2/3 | Recruiting | 661 | Dec 15, 2028 | Registry ↗ |
| Nov 12, 2026 | A Study to Evaluate the Long-term Efficacy and Safety of KarXT + KarX-EC for Agitation in Alzheimer… NCT06937229 · Alzheimer Disease, Agitation KarXT, KarX-EC | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 650 | Jun 22, 2029 | Registry ↗ |
| Nov 12, 2026 | Open-Label Extension Study to Assess the Long-Term Safety and Tolerability of KarXT in Subjects Wit… NCT05980949 · Psychosis Associated With Alzheimer's Disease KarXT | BMY Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | 1,000 | Sep 7, 2027 | Registry ↗ |
| Nov 12, 2026 | A Study of Fedratinib in Japanese Subjects With DIPSS (Dynamic International Prognostic Scoring Sys… NCT04446650 · Primary Myelofibrosis Fedratinib | BMY Bristol-Myers Squibb | Phase 1/2 | Completed was active, not recruiting | 31 | Oct 5, 2023 | Registry ↗ |
| Nov 10, 2026 | Study of Izalontamab Brengitecan (BMS-986507) in Combination With Osimertinib Versus Osimertinib Mo… NCT07680790 · Non-Small Cell Lung Cancer Iza-bren, Osimertinib | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 850 | Dec 30, 2031 | Registry ↗ |
| Nov 10, 2026 | A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism Sp… NCT07285798 · Irritability Associated With Autism Spectrum Disorder KarXT, KarX-EC | BMY Bristol-Myers Squibb | Phase 3 | Recruiting was not yet recruiting | 176 | Aug 6, 2029 | Registry ↗ |
| Nov 10, 2026 | A Study of KarXT + KarX-EC for Treatment of Irritability in Children and Adolescents With Autism NCT07284745 · Irritability Associated With Autism Spectrum Disorder KarXT, KarX-EC | BMY Bristol-Myers Squibb | Phase 3 | Recruiting was not yet recruiting | 176 | Aug 6, 2029 | Registry ↗ |
| Nov 10, 2026 | A Study to Evaluate the Effect of KarXT on Urological Safety NCT07221877 · Schizophrenia Xanomeline/trospium chloride | BMY Bristol-Myers Squibb | Phase 4 | Recruiting | 60 | Dec 30, 2027 | Registry ↗ |
| Nov 10, 2026 | A Study to Evaluate the Efficacy and Safety of KarXT for the Treatment of Manic Episodes in Bipolar… NCT06951711 · Bipolar Disorder Type I With Mania or Mania With Mixed Feat… KarXT, Placebo | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 274 | Nov 2, 2026 | Registry ↗ |
| Nov 10, 2026 | A Study to Compare the Efficacy and Safety of BMS-986489 (Atigotatug+ Nivolumab Fixed Dose Combinat… NCT06646276 · Extensive-Stage Small Cell Lung Cancer BMS-986489 (Atigotatug+Nivolumab), Atezolizumab | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 530 | Aug 17, 2027 | Registry ↗ |
| Nov 9, 2026 | A Study to Compare the Efficacy of Nivolumab and Relatlimab Plus Chemotherapy vs Pembrolizumab Plus… NCT06561386 · Non-small Cell Lung Cancer Nivolumab, Relatlimab | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 1,000 | Jul 30, 2030 | Registry ↗ |
| Nov 6, 2026 | A Study to Evaluate the Metabolism, the Routes and Extent of Elimination, and Drug Levels of [14C]N… NCT07777133 · Healthy Female Participants Navlimetostat, [14C]Navlimetostat | BMY Bristol-Myers Squibb | Phase 1 | Recruiting was not yet recruiting | 6 | Dec 5, 2026 | Registry ↗ |
| Nov 6, 2026 | A Study to Evaluate the Long-term Safety and Tolerability of Xanomeline and Trospium Chloride for t… NCT07424404 · Schizophrenia, Autism-Related Irritability KarXT, KarX-EC | BMY Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | 400 | Mar 8, 2030 | Registry ↗ |
| Nov 6, 2026 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitati… NCT07011732 · Alzheimer Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Ca… | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 426 | Nov 24, 2028 | Registry ↗ |
| Nov 6, 2026 | Pan Tumor Rollover Study NCT03899155 · Cancer Nivolumab, Ipilimumab | BMY Bristol-Myers Squibb | Phase 2 | Recruiting | 1,500 | Aug 25, 2029 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Part… NCT07361497 · Non-small Cell Lung Cancer (NSCLC) Pumitamig, Durvalumab | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 850 | Sep 18, 2030 | Registry ↗ |
| Nov 5, 2026 | A Study to Evaluate the Safety and Efficacy of Pumitamig in Combination With Chemotherapy Versus Ni… NCT07221149 · Untreated Advanced or Metastatic Gastric, Gastroesophageal… Pumitamig, Folfox | BMY Bristol-Myers Squibb | Phase 2/3 | Recruiting | 690 | Nov 8, 2030 | Registry ↗ |
| Nov 5, 2026 | Long-term Outcomes Among Patients With Programmed Death-ligand 1 <1% Metastatic Non-small Cell Lung… NCT07024862 · Metastatic Non-small Cell Lung Cancer nivolumab + ipilimumab | BMY Bristol-Myers Squibb | — | Completed was active, not recruiting | 103 | Aug 28, 2026 | Registry ↗ |
| Nov 5, 2026 | A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in… NCT07015242 · Lymphoma Rituximab, Methotrexate | BMY Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 2 | Recruiting | 65 | Jan 9, 2028 | Registry ↗ |
| Nov 5, 2026 | A Real-World Study of β-Thalassemia Major Treatment With Luspatercept in Taiwan NCT06596642 · β-Thalassemia Major Luspatercept | BMY Bristol-Myers Squibb | — | Completed was active, not recruiting | 61 | Sep 23, 2026 | Registry ↗ |
| Nov 5, 2026 | A Rollover Study of CC-122 NCT05688475 · Non-Hodgkin Lymphoma CC-122, Dexamethasone | BMY Bristol-Myers Squibb | Phase 1 | Active, not recruiting | 12 | Nov 30, 2026 | Registry ↗ |
| Nov 4, 2026 | First-Line Luspatercept in Transfusion-Dependent Lower-Risk Myelodysplastic Neoplasms NCT07752121 · Myelodysplastic Neoplasms Luspatercept | BMY Bristol-Myers Squibb | — | Recruiting was not yet recruiting | 190 | Aug 31, 2030 | Registry ↗ |
| Nov 4, 2026 | A Study of Navlimetostat (BMS-986504) Monotherapy and in Combination With Other Agents in Participa… NCT07492680 · Solid Tumors Navlimetostat, Daraxonrasib | BMY Bristol-Myers Squibb | Phase 2 | Recruiting | 254 | Aug 15, 2028 | Registry ↗ |
| Nov 3, 2026 | A Study to Assess the Relative Bioavailability of Irafamdastat (BMS-986368) and to Assess the Food… NCT07837115 · Healthy Volunteers Irafamdastat | BMY Celgene | Phase 1 | Recruiting was not yet recruiting | 24 | Dec 19, 2026 | Registry ↗ |
| Nov 3, 2026 | A Study to Evaluate the Efficacy and Safety of Adjunctive KarXT for the Treatment of Mania, With or… NCT07140913 · Mania, Bipolar Disorder Xanomeline/Trospium Chloride, Placebo | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 424 | Jun 28, 2027 | Registry ↗ |
| Nov 3, 2026 | A Phase 3 Study to Evaluate the Safety and Efficacy of KarXT + KarX-EC for the Treatment of Agitati… NCT07011745 · Alzheimer's Disease Xanomeline/Trospium Chloride Capsule, Xanomeline Enteric Ca… | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 426 | Nov 3, 2028 | Registry ↗ |
| Nov 2, 2026 | Effectiveness and Adverse-effect Switch Evaluation of Xanomeline and Trospium Chloride (KarXT) NCT07379827 · Schizophrenia Xanomeline and trospium chloride (KarXT) | BMY Bristol-Myers Squibb | — | Recruiting | 1,500 | Jun 20, 2028 | Registry ↗ |
| Nov 2, 2026 | A Study to Assess the Real-World Effectiveness of Mavacamten in Adult Patients With Obstructive Hyp… NCT07361289 · Hypertrophic Cardiomyopathy Mavacamten | BMY Bristol-Myers Squibb | — | Recruiting | 500 | Aug 22, 2028 | Registry ↗ |
| Nov 2, 2026 | Deucravacitinib for Patients With Moderate/Severe Psoriasis: A Real-Life Experience in Italy NCT07256015 · Psoriasis Deucravacitinib | BMY Bristol-Myers Squibb | — | Active, not recruiting was recruiting | 200 | Jul 5, 2027 | Registry ↗ |
| Nov 2, 2026 | Long-Term Safety Outcomes and First-Line Treatment Patterns in Patients With Non-Small Cell Lung Ca… NCT07215962 · Non-small Cell Lung Cancer (NSCLC) Nivolumab + ipilimumab, Nivolumab + ipilimumab + platinum-b… | BMY Bristol-Myers Squibb | — | Completed was active, not recruiting | 300 | Jul 1, 2025 | Registry ↗ |
| Nov 2, 2026 | A Study in Participants With Active Systemic Lupus Erythematosus With Inadequate Response to Glucoc… NCT07175285 · Systemic Lupus Erythematosus (SLE) Current standard of care treatment options | BMY Bristol-Myers Squibb | — | Recruiting | 223 | Mar 24, 2028 | Registry ↗ |
| Nov 2, 2026 | A Study to Evaluate the Efficacy and Safety of KarXT in Acutely Psychotic Japanese Adult Participan… NCT06882785 · Schizophrenia KarXT, Placebo | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 250 | Sep 23, 2028 | Registry ↗ |
| Nov 2, 2026 | Study to Evaluate the Efficacy, Safety, and Tolerability of an Anti-MTBR Tau Monoclonal Antibody (B… NCT06268886 · Alzheimer Disease, Early Onset BMS-986446, Placebo | BMY Bristol-Myers Squibb | Phase 2 | Active, not recruiting | 310 | Dec 17, 2026 | Registry ↗ |
| Nov 2, 2026 | Long-Term Follow-up Protocol for Participants Treated With Gene-Modified T Cells NCT03435796 · Neoplasms Gene-modified (GM) T cell therapy | BMY Celgene | Phase 2/3 | Recruiting | 1,541 | May 29, 2043 | Registry ↗ |
| Nov 2, 2026 | Study of Nivolumab in Combination With Ipilimumab or Standard of Care Chemotherapy Compared to the… NCT03036098 · Urothelial Cancer Nivolumab, Ipilimumab | BMY Bristol-Myers Squibb | Phase 3 | Completed was active, not recruiting | 1,314 | Aug 30, 2024 | Registry ↗ |
| Oct 30, 2026 | Relapse Prevention Trial Evaluating KarXT Treatment in Schizophrenia NCT07686263 · Schizophrenia Xanomeline/Trospium Chloride, Placebo | BMY Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | 472 | Mar 3, 2029 | Registry ↗ |
| Oct 30, 2026 | Long-term Extension Study to Evaluate Safety and Tolerability of Admilparant in Participants With P… NCT07441408 · Pulmonary Fibrosis BMS-986278 | BMY Bristol-Myers Squibb | Phase 3 | Not yet recruiting | 2,380 | Nov 22, 2029 | Registry ↗ |
| Oct 30, 2026 | A Study to Evaluate Mezigdomide, Bortezomib and Dexamethasone (MEZIVd) Versus Pomalidomide, Bortezo… NCT05519085 · Relapsed or Refractory Multiple Myeloma mezigdomide, Pomalidomide | BMY Celgene | Phase 3 | Recruiting | 810 | Jan 10, 2027 | Registry ↗ |
| Oct 30, 2026 | Phase 2 Trial of Adagrasib Monotherapy and in Combination With Pembrolizumab and a Phase 3 Trial of… NCT04613596 · Advanced Non-Small Cell Lung Cancer, Metastatic Non-Small C… Adagrasib, Adagrasib | BMY Mirati Therapeutics Inc. | Phase 2/3 | Recruiting | 626 | Oct 31, 2028 | Registry ↗ |
| Oct 29, 2026 | A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Particip… NCT06615479 · Relapsed or Refractory Multiple Myeloma (RRMM) BMS-986393, Cyclophosphamide | BMY Juno Therapeutics, Inc., a Bristol-Myers Squibb Company | Phase 3 | Recruiting | 440 | Dec 30, 2027 | Registry ↗ |
| Oct 28, 2026 | Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMA… NCT07116967 · Plaque Psoriasis Deucravacitinib, Ustekinumab | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 3,040 | Jan 16, 2031 | Registry ↗ |
| Oct 28, 2026 | A Study of MORAb-202 Versus Investigator's Choice Chemotherapy in Female Participants With Platinum… NCT05613088 · Neoplasms, Ovarian MORAb-202, Paclitaxel | BMY Bristol-Myers Squibb | Phase 2 | Terminated | 106 | Jun 17, 2024 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adoles… NCT06979453 · Plaque Psoriasis Deucravacitinib, Placebo | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 366 | Oct 12, 2029 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Efficacy and Safety of KarXT + KarX-EC for Cognitive Impairment in Alzheime… NCT06976216 · Alzheimer's Disease KarXT, KarX-EC | BMY Bristol-Myers Squibb | Phase 3 | Recruiting | 586 | Sep 11, 2028 | Registry ↗ |
| Oct 27, 2026 | A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemo… NCT06875310 · Carcinoma, Non-Small-Cell Lung Adagrasib, Pembrolizumab | BMY Mirati Therapeutics Inc. | Phase 3 | Recruiting | 630 | Sep 7, 2029 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate the Efficacy, Safety and Tolerability of BMS-986368 in Participants With Multip… NCT06782490 · Multiple Sclerosis Spasticity BMS-986368, Placebo | BMY Celgene | Phase 2 | Recruiting | 200 | May 26, 2027 | Registry ↗ |
| Oct 27, 2026 | A Study to Evaluate KarXT as a Treatment for Psychosis Associated With Alzheimer's Disease (ADEPT-4) NCT06585787 · Alzheimer Disease KarXT, Placebo | BMY Karuna Therapeutics, Inc., a Bristol Myers Squibb company | Phase 3 | Recruiting | 406 | Nov 24, 2026 | Registry ↗ |
The newest 50 items, most recent first. Each row links to the study's page on ClinicalTrials.gov. Updated Nov 15, 2026, 6:55 PM EST.
Download CSV The rows of this feed, with the filters above. A download holds at most 10,000 rows; narrow the filters to get a smaller slice.
Other feeds: Congressional trades · Executive-branch trades · Bills in Congress · Roll-call votes · Corporate PAC donations · Lobbying · Capitol Hires · Lobbying and contracts · Government contracts · Insider trades · Planned insider sales · Executive pay · Ownership stakes (13D / 13G) · Institutional holdings (13F) · Short interest · Fails to deliver · Daily short volume · Wikipedia page views · App store ratings · H-1B visa applications · Stock splits · 8-K events · IPO filings · Deals · Private placements (Form D) · Merger clearances (HSR) · Layoff notices (WARN) · SEC enforcement · Patents · FDA approvals and clearances